| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 41 | Mutant-selective EGFR inhibitors and uses thereof | US14448578 | 2014-07-31 | US09409887B2 | 2016-08-09 | Kwangho Lee; Deqiang Niu; Matthew F. Baevsky |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 42 | 4,6-disubstituted pyrimidines as kinase inhibitors | US14693489 | 2015-04-22 | US09393246B2 | 2016-07-19 | Juswinder Singh; Shomir Ghosh; Arthur Kluge; Russell C. Petter; Richland W. Tester |
| The present invention provides 4,6-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 43 | COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS | US14189008 | 2014-02-25 | US20150366955A9 | 2015-12-24 | VAFA SHAHABI; Anu Wallecha; Paulo C. Maciag; Yvonne Paterson; Nicola Mason; Matthew M. Seavey |
| This invention provides compositions and methods for treating and vaccinating against a Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a non-human animal. | ||||||
| 44 | HETEROARYL COMPOUNDS AND USES THEREOF | US14693489 | 2015-04-22 | US20150328223A1 | 2015-11-19 | Juswinder Singh; Shomir Ghosh; Arthur Kluge; Russell C. Petter; Richland W. Tester |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 45 | Preeclamptic Placental Mesenchymal Stem Cell Conditioned Medium for Use in the Treatment of a Tumour | US14432722 | 2013-10-02 | US20150250823A1 | 2015-09-10 | Alessandro Rolfo; Tullia Todros |
| It is described a conditioned medium (CM) obtainable by culturing, in a liquid culture medium, placental mesenchymal stem cells from a preeclamptic placenta. The conditioned medium object of the invention includes at least IP-10 and TARC proteins and it is used for the therapeutic treatment of a tumor, preferably an epithelial tumor. | ||||||
| 46 | COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS | US14189008 | 2014-02-25 | US20150238584A1 | 2015-08-27 | VAFA SHAHABI; Anu Wallecha; Paulo C. Maciag; Yvonne Paterson; Nicola Mason; Matthew M. Seavey |
| This invention provides compositions and methods for treating and vaccinating against a Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a non-human animal. | ||||||
| 47 | TREATMENT OF AMD USING AAV SFLT-1 | US14281749 | 2014-05-19 | US20150004101A1 | 2015-01-01 | Ian J. Constable; P. Elizabeth Rakoczy; Chooi-May Lai; Thomas W. Chalberg, JR. |
| The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject. | ||||||
| 48 | TREATMENT OF AMD USING AAV SFLT-1 | US14281783 | 2014-05-19 | US20140371438A1 | 2014-12-18 | Ian J. Constable; P. Elizabeth Rakoczy; Chooi-May Lai; Thomas W. Chalberg, JR. |
| The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject. | ||||||
| 49 | TREATMENT OF AMD USING AAV SFLT-1 | US14281765 | 2014-05-19 | US20140341977A1 | 2014-11-20 | Ian J. Constable; Elizabeth P. Rakoczy; Chooi-May Lai; Thomas W. Chalberg, JR. |
| The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject. | ||||||
| 50 | 4,6-disubstituted pyrimidines useful as kinase inhibitors | US13018624 | 2011-02-01 | US08445498B2 | 2013-05-21 | Juswinder Singh; Shomir Ghosh; Arthur F. Kluge; Russell C. Petter; Richland W. Tester |
| The present invention provides 4,6-disubstituted pyrimidine compound useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 51 | TPM4-ALK fusion protein and composition for diagnosing cancer | US15949066 | 2018-04-09 | US20180299451A1 | 2018-10-18 | Ze Won PARK; Dae Young ZANG; Young Ho KOH |
| Background: Recently, studies on genome and transcritome of gastric cancer have suggested that gastric cancer is a heterogeneous disease caused by various genetic defects combined with environmental risk factors. In the present invention, a fusion protein expressed only in Korean gastric cancer tissues is detected by performing quantitative label-free proteome analysis.Result: A tropomyosin 4 (TPM4)-anaplastic lymphoma receptor tyrosine kinase (ALK) fusion protein, which is not expressed in a normal gastric tissue, but expressed only in a gastric cancer tissue, is identified. As a result identified by the TPM4 antibody, a high-molecular TPM4 band is present only in a gastric cancer tissue. | ||||||
| 52 | Muscle specific tyrosine kinase-fluorophore conjugate compositions, kits and methods of using | US14835934 | 2015-08-26 | US10093743B2 | 2018-10-09 | Premkumar Christadoss |
| Provided herein is a method of diagnosing muscle specific tyrosine kinase specific autoimmune myasthenia gravis in an individual. Generally, in the method a level of muscle specific tyrosine kinase binding to B cells is determined in a sample from an individual. A significant increase in the level of muscle specific tyrosine kinase reactive B-cells compared to that in a healthy individual indicates the presence of muscle specific tyrosine kinase autoimmune myasthenia gravis. Also provided is a fluorophore-muscle specific tyrosine kinase conjugate and a kit comprising the same useful to test the frequency of muscle specific tyrosine kinase binding B cells expressing specific markers, for diagnosis or as biomarker for muscle specific tyrosine kinase autoimmune myasthenia gravis. | ||||||
| 53 | COMPOSITIONS TARGETING THE INTERACTION DOMAIN BETWEEN P27KIP1 AND BRK AND METHODS OF USE THEREOF TO INHIBIT P27 Y PHOSPHORYLATION AND CDK4 ACTIVITY | US15351904 | 2016-11-15 | US20170065662A1 | 2017-03-09 | Stacy W. Blain |
| Compositions and methods for the treatment of malignancy are disclosed. | ||||||
| 54 | NOVEL ISOFORM OF ANAPLASTIC LYMPHOMA KINASE AND ITS USES | US15288531 | 2016-10-07 | US20170022485A1 | 2017-01-26 | Ping Chi; Thomas Wiesner; Yu Chen |
| The present invention relates to a Truncated isoform of Anaplastic Lymphoma Kinase (“TALK”). Expression of this isoform is associated with malignancy and with responsiveness to ALK inhibitors. Detection of the isoform may be used in diagnostic and therapeutic methods. Because it arises as a result of variant transcription rather than genetic rearrangement, its presence would be undetected by genomic testing. | ||||||
| 55 | HETEROARYL COMPOUNDS AND USES THEREOF | US15208368 | 2016-07-12 | US20160311780A1 | 2016-10-27 | Juswinder Singh; Shomir Ghosh; Arthur F. Kluge; Russell C. Petter; Richland Wayne Tester |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 56 | IDENTIFICATION OF MOLECULAR PATHWAYS AND METHODS OF USE THEREOF FOR TREATING RETINAL NEURODEGENERATION AND OTHER NEURODEGENERATIVE DISORDERS | US14383982 | 2013-03-11 | US20150030572A1 | 2015-01-29 | Donald J. Zack; Derek S. Welsbie |
| Drug targets, pathways, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed. | ||||||
| 57 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | US14448578 | 2014-07-31 | US20150025055A1 | 2015-01-22 | Kwangho Lee; Deqiang Niu; Russell C. Petter; Juswinder Singh; Matthew F. Baevsky; Bruce Eaton; Zhendong Zhu; Laura A. D'Agostino |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 58 | Mutant-selective EGFR inhibitors and uses thereof | US13291706 | 2011-11-08 | US08796255B2 | 2014-08-05 | Kwangho Lee; Deqiang Niu; Matthew F. Baevsky |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 59 | TREATMENT OF AMD USING AAV SFLT-1 | US13889275 | 2013-05-07 | US20130323302A1 | 2013-12-05 | Ian J. Constable; Elizabeth P. Rakoczy; Chooi-May Lai; Thomas W. Chalberg, JR. |
| The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject. | ||||||
| 60 | HETEROARYL COMPOUNDS AND USES THEREOF | US13018624 | 2011-02-01 | US20110230494A1 | 2011-09-22 | Juswinder Singh; Shomir Ghosh; Arthur F. Kluge; Russell C. Petter; Richland W. Tester |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
QQ群二维码
意见反馈
意见反馈